journal article·2013-10

Microemulsion extrusion technique: a new method to produce lipid nanoparticles

Marcelo Bispo de Jesus, Allan Radaic, Inge S. Zuhorn, Eneida de Paula

Journal of Nanoparticle Research· Volume 15· Issue 10
Publisher page

Abstract

Solid lipid nanoparticles (SLN) and nano-structured lipid carriers (NLC) have been intensively investigated for different applications, including their use as drug and gene delivery systems. Different techniques have been employed to produce lipid nanoparticles, of which high pressure homogenization is the standard technique that is adopted nowadays. Although this method has a high efficiency, does not require the use of organic solvents, and allows large-scale production, some limitations impede its application at laboratory scale: the equipment is expensive, there is a need of huge amounts of surfactants and co-surfactants during the preparation, and the operating conditions are energy intensive. Here, we present the microemulsion extrusion technique as an alternative method to prepare lipid nanoparticles. The parameters to produce lipid nanoparticles using microemulsion extrusion were established, and the lipid particles produced (SLN, NLC, and liposomes) were characterized with regard to size (from 130 to 190 nm), zeta potential, and drug (mitoxantrone) and gene (pDNA) delivery properties. In addition, the particles' in vitro co-delivery capacity (to carry mitoxantrone plus pDNA encoding the phosphatase and tensin homologue, PTEN) was tested in normal (BALB3T3 fibroblast) and cancer (PC3 prostate and MCF-7 breast) cell lines. The results show that the microemulsion extrusion technique is fast, inexpensive, reproducible, free of organic solvents, and suitable for small volume preparations of lipid nanoparticles. Its application is particularly interesting when using rare and/or costly drugs or ingredients (e. g., cationic lipids for gene delivery or labeled lipids for nanoparticle tracking/diagnosis).
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Lipid Membrane Structure and Behavior · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (38)

Show source-provided references
1. Alberts D, Peng Y, Bowden GT et al (1985) Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Invest New Drugs 3:101–107. doi: 10.1007/BF0017415610.1007/BF00174156 ↗
2. Anton N, Benoit J-P, Saulnier P (2008) Design and production of nanoparticles formulated from nano-emulsion templates-a review. J Control Release 128:185–199. doi: 10.1016/j.jconrel.2008.02.00710.1016/j.jconrel.2008.02.007 ↗
3. Attama AA (2011) SLN, NLC, LDC: state of the art in drug and active delivery. Recent Pat Drug Deliv Formul 5:178–18710.2174/187221111797200524 ↗
4. Battaglia L, Gallarate M (2012) Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery. Expert Opin Drug Deliv 9:497–508. doi: 10.1517/17425247.2012.67327810.1517/17425247.2012.673278 ↗
5. Bertani G (2004) Lysogeny at mid-twentieth century: P1, P2, and other experimental systems. J Bacteriol 186:595–600. doi: 10.1128/JB.186.3.595-60010.1128/JB.186.3.595-600.2004 ↗
6. Bondi ML, Craparo EF (2010) Solid lipid nanoparticles for applications in gene therapy: a review of the state of the art. Expert Opin Drug Deliv 7:7–18. doi: 10.1517/1742524090336241010.1517/17425240903362410 ↗
7. Bunjes H, Steiniger F, Richter W (2007) Visualizing the structure of triglyceride nanoparticles in different crystal modifications. Langmuir 23:4005–4011. doi: 10.1021/la062904p10.1021/la062904p ↗
8. Chen S, Zhao D, Li F et al (2012) Co-delivery of genes and drugs with nanostructured calcium carbonate for cancer therapy. RSC Adv 2:1820–1826. doi: 10.1039/c1ra00527h10.1039/c1ra00527h ↗
9. Corrias F, Lai F (2011) New methods for lipid nanoparticles preparation. Recent Pat Drug Deliv Formul 5:201–21310.2174/187221111797200597 ↗
10. Das S, Chaudhury A (2011) Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 12:62–76. doi: 10.1208/s12249-010-9563-010.1208/s12249-010-9563-0 ↗
11. del Pozo-Rodríguez A, Delgado D, Solinís MÁ et al (2010) Solid lipid nanoparticles as potential tools for gene therapy: in vivo protein expression after intravenous administration. Int J Pharm 385:157–162. doi: 10.1016/j.ijpharm.2009.10.02010.1016/j.ijpharm.2009.10.020 ↗
12. Gasco M (2007) Lipid nanoparticles: perspectives and challenges. Adv Drug Deliv Rev 59:377–378. doi: 10.1016/j.addr.2007.05.00410.1016/j.addr.2007.05.004 ↗
13. Hecht LL, Wagner C, Landfester K, Schuchmann HP (2011) Surfactant concentration regime in miniemulsion polymerization for the formation of MMA nanodroplets by high-pressure homogenization. Langmuir 27:2279–2285. doi: 10.1021/la104480s10.1021/la104480s ↗
14. Hinrichs WLJ, Manceñido FA, Sanders NN et al (2006) The choice of a suitable oligosaccharide to prevent aggregation of PEGylated nanoparticles during freeze thawing and freeze drying. Int J Pharm 311:237–244. doi: 10.1016/j.ijpharm.2005.12.03210.1016/j.ijpharm.2005.12.032 ↗
15. Jiang B-H, Liu L-Z (2008) PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta 1784:150–158. doi: 10.1016/j.bbapap.2007.09.00810.1016/j.bbapap.2007.09.008 ↗
16. Jiang Z, Pore N, Cerniglia GJ et al (2007) Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. Cancer Res 67:4467–4473. doi: 10.1158/0008-5472.CAN-06-339810.1158/0008-5472.CAN-06-3398 ↗
17. Justo OR, Moraes ÂM (2011) Analysis of process parameters on the characteristics of liposomes prepared by ethanol injection with a view to process scale-up: effect of temperature and batch volume. Chem Eng Res Des 89:785–792. doi: 10.1016/j.cherd.2010.09.01810.1016/j.cherd.2010.09.018 ↗
18. Kuntsche J, Horst JC, Bunjes H (2011) Cryogenic transmission electron microscopy (cryo-TEM) for studying the morphology of colloidal drug delivery systems. Int J Pharm 417:120–137. doi: 10.1016/j.ijpharm.2011.02.00110.1016/j.ijpharm.2011.02.001 ↗
19. Liedtke S, Wissing S, Müller RH, Mäder K (2000) Influence of high pressure homogenisation equipment on nanodispersions characteristics. Int J Pharm 196:183–18510.1016/S0378-5173(99)00417-2 ↗
20. Lu B, Xiong S-B, Yang H et al (2006) Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases. Eur J Pharm Sci 28:86–95. doi: 10.1016/j.ejps.2006.01.00110.1016/j.ejps.2006.01.001 ↗
21. MacDonald RC, MacDonald RI, Menco BP et al (1991) Small-volume extrusion apparatus for preparation of large, unilamellar vesicles. Biochim Biophys Acta 1061:297–30310.1016/0005-2736(91)90295-J ↗
22. Mahon KL, Henshall SM, Sutherland RL, Horvath LG (2011) Pathways of chemotherapy resistance in castration-resistant prostate cancer. Endocr Relat Cancer 18:R103–R123. doi: 10.1530/ERC-10-034310.1530/ERC-10-0343 ↗
23. Manjunath K, Reddy JS, Venkateswarlu V (2005) Solid lipid nanoparticles as drug delivery systems. Methods Find Exp Clin Pharmacol 27:127–144. doi: 10.1358/mf.2005.27.2.87628610.1358/mf.2005.27.2.876286 ↗
24. Mehnert W, Mäder K (2001) Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 47:165–19610.1016/S0169-409X(01)00105-3 ↗
25. Muchow M, Maincent P, Müller RH (2008) Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm 34:1394–1405. doi: 10.1080/0363904080213006110.1080/03639040802130061 ↗
26. Mukherjee S, Ray S, Thakur RS (2009) Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci 71:349–358. doi: 10.4103/0250-474X.5728210.4103/0250-474X.57282 ↗
27. Müller RH, Mäder K, Gohla S (2000) Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 50:161–17710.1016/S0939-6411(00)00087-4 ↗
28. Puglia C, Bonina F (2012) Lipid nanoparticles as novel delivery systems for cosmetics and dermal pharmaceuticals. Expert Opin Drug Deliv 9:429–441. doi: 10.1517/17425247.2012.66696710.1517/17425247.2012.666967 ↗
29. Puri A, Loomis K, Smith B et al (2009) Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst 26:523–58010.1615/CritRevTherDrugCarrierSyst.v26.i6.10 ↗
30. Sahay G, Alakhova DY, Kabanov AV (2010) Endocytosis of nanomedicines. J Control Release 145:182–195. doi: 10.1016/j.jconrel.2010.01.03610.1016/j.jconrel.2010.01.036 ↗
31. Schwarz C, Mehnert W (1997) Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN). Int J Pharm 157:171–17910.1016/S0378-5173(97)00222-6 ↗
32. Souto EB, Severino P, Santana MHA, Pinho SC (2011) Solid lipid nanoparticles: classical methods of lab production. Quim Nova 34:1762–1769
33. Vighi E, Ruozi B, Montanari M et al (2010) pDNA condensation capacity and in vitro gene delivery properties of cationic solid lipid nanoparticles. Int J Pharm 389:254–261. doi: 10.1016/j.ijpharm.2010.01.03010.1016/j.ijpharm.2010.01.030 ↗
34. Yu YH, Kim E, Park DE et al (2012) Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA. Eur J Pharm Biopharm 80:268–273. doi: 10.1016/j.ejpb.2011.11.00210.1016/j.ejpb.2011.11.002 ↗
35. Zhang S, Yang X, Morris ME (2004) Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 65:1208–1216. doi: 10.1124/mol.65.5.120810.1124/mol.65.5.1208 ↗
36. Zhang J, Fan Y, Smith E (2009) Experimental design for the optimization of lipid nanoparticles. J Pharm Sci 98:1813–1819. doi: 10.1002/jps.2154910.1002/jps.21549 ↗
37. Zhang F, Throm SL, Murley LL et al (2011a) MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport. Biochem Pharmacol 82:24–34. doi: 10.1016/j.bcp.2011.03.02410.1016/j.bcp.2011.03.024 ↗
38. Zhang P, Ling G, Pan X et al (2011b) Novel nanostructured lipid-dextran sulfate hybrid carriers overcome tumor multidrug resistance of mitoxantrone hydrochloride. Nanomedicine 8:185–193. doi: 10.1016/j.nano.2011.06.00710.1016/j.nano.2011.06.007 ↗